Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation

特立帕肽 德诺苏马布 医学 经济评价 双膦酸盐 骨质疏松症 雷洛昔芬 成本效益 梅德林 荟萃分析 内科学 骨矿物 风险分析(工程) 三苯氧胺 癌症 乳腺癌 政治学 法学 病理
作者
Sarah Davis,Emma L. Simpson,Jean Hamilton,Marrissa Martyn‐St James,Andrew Rawdin,Ruth Wong,Edward Goka,Neil J. L. Gittoes,Peter L. Selby
出处
期刊:Health Technology Assessment [NIHR Journals Library]
卷期号:24 (29): 1-314 被引量:177
标识
DOI:10.3310/hta24290
摘要

Background Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. Objectives The objectives were to evaluate the clinical effectiveness, safety and cost-effectiveness of non-bisphosphonates {denosumab [Prolia ® ; Amgen Inc., Thousand Oaks, CA, USA], raloxifene [Evista ® ; Daiichi Sankyo Company, Ltd, Tokyo, Japan], romosozumab [Evenity ® ; Union Chimique Belge (UCB) S.A. (Brussels, Belgium) and Amgen Inc.] and teriparatide [Forsteo ® ; Eli Lilly and Company, Indianapolis, IN, USA]}, compared with each other, bisphosphonates or no treatment, for the prevention of fragility fracture. Data sources For the clinical effectiveness review, nine electronic databases (including MEDLINE, EMBASE and the World Health Organization International Clinical Trials Registry Platform) were searched up to July 2018. Review methods A systematic review and network meta-analysis of fracture and femoral neck bone mineral density were conducted. A review of published economic analyses was undertaken and a model previously used to evaluate bisphosphonates was adapted. Discrete event simulation was used to estimate lifetime costs and quality-adjusted life-years for a simulated cohort of patients with heterogeneous characteristics. This was done for each non-bisphosphonate treatment, a strategy of no treatment, and the five bisphosphonate treatments previously evaluated. The model was populated with effectiveness evidence from the systematic review and network meta-analysis. All other parameters were estimated from published sources. An NHS and Personal Social Services perspective was taken, and costs and benefits were discounted at 3.5% per annum. Fracture risk was estimated from patient characteristics using the QFracture ® (QFracture-2012 open source revision 38, Clinrisk Ltd, Leeds, UK) and FRAX ® (web version 3.9, University of Sheffield, Sheffield, UK) tools. The relationship between fracture risk and incremental net monetary benefit was estimated using non-parametric regression. A probabilistic sensitivity analysis and scenario analyses were used to assess uncertainty. Results Fifty-two randomised controlled trials of non-bisphosphonates were included in the clinical effectiveness systematic review and an additional 51 randomised controlled trials of bisphosphonates were included in the network meta-analysis. All treatments had beneficial effects compared with placebo for vertebral, non-vertebral and hip fractures, with hazard ratios varying from 0.23 to 0.94, depending on treatment and fracture type. The effects on vertebral fractures and the percentage change in bone mineral density were statistically significant for all treatments. The rate of serious adverse events varied across trials (0–33%), with most between-group differences not being statistically significant for comparisons with placebo/no active treatment, non-bisphosphonates or bisphosphonates. The incremental cost-effectiveness ratios were > £20,000 per quality-adjusted life-year for all non-bisphosphonate interventions compared with no treatment across the range of QFracture and FRAX scores expected in the population eligible for fracture risk assessment. The incremental cost-effectiveness ratio for denosumab may fall below £30,000 per quality-adjusted life-year at very high levels of risk or for high-risk patients with specific characteristics. Raloxifene was dominated by no treatment (resulted in fewer quality-adjusted life-years) in most risk categories. Limitations The incremental cost-effectiveness ratios are uncertain for very high-risk patients. Conclusions Non-bisphosphonates are effective in preventing fragility fractures, but the incremental cost-effectiveness ratios are generally greater than the commonly applied threshold of £20,000–30,000 per quality-adjusted life-year. Study registration This study is registered as PROSPERO CRD42018107651. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 29. See the NIHR Journals Library website for further project information.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Pdnnnnn完成签到,获得积分10
刚刚
AJ只想逛街完成签到,获得积分10
刚刚
369ninja发布了新的文献求助10
刚刚
CX发布了新的文献求助10
刚刚
刚刚
赘婿的应助被Tongtong采纳,获得10
1秒前
2秒前
CipherSage的应助被lethe采纳,获得10
2秒前
科研之路发布了新的文献求助10
2秒前
水煮电吹风的应助被Code_king采纳,获得10
2秒前
2秒前
水煮电吹风的应助被Code_king采纳,获得10
2秒前
Nora发布了新的文献求助10
2秒前
水煮电吹风的应助被Code_king采纳,获得10
2秒前
水煮电吹风的应助被Code_king采纳,获得10
2秒前
秋风的应助被Code_king采纳,获得10
3秒前
123的应助被Code_king采纳,获得10
3秒前
123的应助被Code_king采纳,获得10
3秒前
水煮电吹风的应助被Code_king采纳,获得10
3秒前
奔跑的应助被Code_king采纳,获得10
3秒前
水煮电吹风的应助被Code_king采纳,获得10
3秒前
塔莉娅完成签到,获得积分10
3秒前
许艺议完成签到 ,获得积分10
4秒前
酷酷柚子发布了新的文献求助10
4秒前
小番茄发布了新的文献求助10
4秒前
4秒前
Felicity完成签到 ,获得积分10
4秒前
吃米线的应助被生而追梦不止采纳,获得10
4秒前
4秒前
橘柚完成签到 ,获得积分10
4秒前
jiashan发布了新的文献求助10
5秒前
5秒前
5秒前
高贵芝麻完成签到,获得积分10
5秒前
6秒前
今后的应助被能干的板凳采纳,获得10
6秒前
今后的应助被bobo采纳,获得10
6秒前
6秒前
科研通AI6.3的应助被1900采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460